Structural mechanism for specific binding of chemical compounds to amyloid fibrils

Youqi Tao,Wencheng Xia,Qinyue Zhao,Huaijiang Xiang,Chao Han,Shenqing Zhang,Wei Gu,Wenjun Tang,Ying Li,Li Tan,Dan Li,Cong Liu

DOI: https://doi.org/10.1038/s41589-023-01370-x

IF: 14.8

2023-07-04

Nature Chemical Biology

Abstract:Amyloid fibril is an important pharmaceutical target for diagnostic and therapeutic treatment of neurodegenerative diseases. However, rational design of chemical compounds that interact with amyloid fibrils is unachievable due to the lack of mechanistic understanding of the ligand–fibril interaction. Here we used cryoelectron microscopy to survey the amyloid fibril-binding mechanism of a series of compounds including classic dyes, (pre)clinical imaging tracers and newly identified binders from high-throughput screening. We obtained clear densities of several compounds in complex with an α-synuclein fibril. These structures unveil the basic mechanism of the ligand–fibril interaction, which exhibits remarkable difference from the canonical ligand–protein interaction. In addition, we discovered a druggable pocket that is also conserved in the ex vivo α-synuclein fibrils from multiple system atrophy. Collectively, these findings expand our knowledge of protein–ligand interaction in the amyloid fibril state, which will enable rational design of amyloid binders in a medicinally beneficial way.

biochemistry & molecular biology

What problem does this paper attempt to address?

This paper aims to solve the problem of how to design small - molecule compounds that can specifically bind to amyloid fibrils. Specifically, amyloid fibrils are formed by proteins such as tau, α - synuclein (α - syn) and β - amyloid. These fibrils have important pathological significance in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. However, due to the lack of in - depth understanding of the interaction mechanism between small molecules and amyloid fibrils, the rational design of chemical compounds targeting amyloid fibrils has been a challenge. To overcome this problem, researchers used cryo - electron microscopy (cryo - EM) technology to investigate the binding mechanisms of a series of compounds (including classical dyes, clinical or pre - clinical imaging tracers, and newly discovered binders through high - throughput screening) to α - synuclein amyloid fibrils. The research results revealed the basic mechanisms of these compounds binding to amyloid fibrils, which are significantly different from the classical ligand - protein interaction mechanisms. In addition, the study also discovered a drug pocket that is also conservatively present in α - synuclein amyloid fibrils extracted from patients with multiple system atrophy, which provides new possibilities for the rational design of amyloid fibril binders. In summary, this study has expanded our understanding of protein - ligand interactions in the amyloid fibril state and laid the foundation for the design and engineering of medically beneficial amyloid fibril binders.

Structural mechanism for specific binding of chemical compounds to amyloid fibrils

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Binding adaptability of chemical ligands to polymorphic α-synuclein amyloid fibrils

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Conformational Dynamics of an α-Synuclein Fibril upon Receptor Binding Revealed by Insensitive Nuclei Enhanced by Polarization Transfer-Based Solid-State Nuclear Magnetic Resonance and Cryo-Electron Microscopy

Identification of a Novel Parallel Β‐strand Conformation Within Molecular Monolayer of Amyloid Peptide

Α-Helical Motif As Inhibitors of Toxic Amyloid-β Oligomer Generation Via Highly Specific Recognition of Amyloid Surface

Structure-Based Peptide Inhibitor Design of Amyloid-β Aggregation

Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

De Novo Design of Cross-α Amyloid-Like Fibrils with Cellular Activity

Coupling of the Non-Amyloid-component (NAC) Domain and the KTK(E/Q)GV Repeats Stabilize the Α-Synuclein Fibrils.

In Silico Study of Recognition Between Aβ40 and Aβ40 Fibril Surfaces: an N-Terminal Helical Recognition Motif and Its Implications for Inhibitor Design

Engineering Core/Ligands Interfacial Anchors of Nanoparticles for Efficiently Inhibiting Both Aβ and Amylin Fibrillization

Rationally Designed Amyloid Inhibitors Based on Amyloid-Related Structural Studies

Recent Studies On Mechanisms Of New Drug Candidates For Alzheimer'S Disease Interacting With Amyloid-Beta Protofibrils Using Molecular Dynamics Simulations

Aβ-binding molecules: Possible application as imaging probes and as anti-aggregation agents

Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy

Design of amyloidogenic peptide traps

The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils